Form 8-K - Current report:
SEC Accession No. 0001104659-24-129181
Filing Date
2024-12-17
Accepted
2024-12-17 07:10:42
Documents
15
Period of Report
2024-12-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2431191d1_8k.htm   iXBRL 8-K 24726
2 EXHIBIT 99.1 tm2431191d1_ex99-1.htm EX-99.1 16656
6 GRAPHIC tm2431191d1_ex99-1img001.jpg GRAPHIC 6371
  Complete submission text file 0001104659-24-129181.txt   231223

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20241217.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20241217_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20241217_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2431191d1_8k_htm.xml XML 3808
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 241553644
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)